Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial | Lifestyle Behaviors | JAMA

This clinical trial compares the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily subcutaneous liraglutide, 3.

Related Keywords

Helsinki ,Eteläuomen Läi ,Finland ,United States ,American ,Domenicam Rubino ,Jenny Craig ,Novmeta Pharma ,Sophie Walton ,Gedeon Richter Pharma ,Eli Lilly ,Novo Nordisk ,Spirit Medical Communications Group ,Genentech ,Endocrine Society ,Jazz Pharmaceuticals ,Boehringer Ingelheim ,American Diabetes Association ,Washington Center ,Novartis ,Pfizer ,Astrazeneca ,Dr Reddy Lab ,Academic Technology Ventures ,Nutrition Corp ,Slim Health Nutrition ,Group Information ,International Conference On Harmonization Good Clinical Practice ,Drug Administration ,Obesity Society ,Gedeon Richter ,Ww International ,Pennington Biomedical Research Center ,University Of Pennsylvania ,Institute Inc ,Ketogenic Health Systems ,Pearson ,Robard Corporation ,Treatment Effect ,People With Obesity ,International Conference ,Harmonization Good Clinical Practice ,Size Calculation ,Secondary Outcomes ,Hoc Outcomes ,Weight Management ,Drs Rubino ,Interest Disclosures ,Melior Discoveries ,Basic Research ,General Nutrition Corp ,Epitomee Medical ,Applied Therapeutics ,Weight Watchers ,Spirit Medical Communications Group Limited ,Semaglutide Treatment Effect ,